

CURRICULUM VITAE

DATE: September 2020
NAME: YIYAN LIU, MD, PhD
PRESENT TITLE: Professor
HOME ADDRESS: 132 Eastview Ave, Leonia, NJ 07605
OFFICE ADDRESS: University Hospital
Nuclear Medicine
150 Bergen Street, H-140
Newark, NJ 07101

TELEPHONE NUMBER/E-MAILADDRESS: 973-972-6022/liuyl@njms.rutgers.edu

CITIZENSHIP: U.S.A. citizen

EDUCATION:

- A. Tongji Medical University, Wuhan, China
PhD, July 1990
- B. Tongji Medical University, Wuhan, China
MD, July 1983

POST-DOCTORAL TRAINING:

- A. Internships and Residencies
 - Albert Einstein College of Medicine, Bronx, New York
Department of Nuclear Medicine
PET fellowship
07/2003 – 06/2004
 - Albert Einstein College of Medicine, Bronx, New York
Department of Nuclear Medicine
Resident
07/2001 – 06/2003
 - Sound Shore Medical Center, New Rochelle, New York
Department of Surgery
Internship
07/2000 – 06/2001
 - Union Hospital, Tongji Medical University, Wuhan, China
Department of Urology
 - Resident & Chief Resident
07/1983 – 06/1989

B. Research Fellowships

University of Maryland at Baltimore, Baltimore, Maryland
Department of Physiology
Postdoctoral Research Fellowship
01/1993 – 06/2000

ACADEMIC APPOINTMENTS:

Professor
Department of Radiology
Rutgers University-New Jersey Medical School, Newark, New Jersey
07/2018 – Present

Associate Professor
Department of Radiology
Rutgers University-New Jersey Medical School, Newark, New Jersey
07/2010 – 06/2018

Assistant Professor
Department of Radiology
Rutgers University-New Jersey Medical School, Newark, New Jersey
07/2004 – 06/2010

Associate Professor
Department of Surgery
Tongji Medical University, Wuhan, China
07/1992 – 01/1993

Assistant Professor
Department of Surgery
Tongji Medical University, Wuhan, China
07/1990 – 06/1992

HOSPITAL APPOINTMENTS:

Medical Director
Nuclear Medicine Section and PET/CT Center
Department of Radiology
Rutgers University-University Hospital, Newark, New Jersey
08/2019-Present

Section Chief
Nuclear Medicine Section and PET/CT Center
Department of Radiology
Rutgers University-University Hospital, Newark, New Jersey
01/2019-07/2019

Attending physician
Department of Radiology
Rutgers University-University Hospital, Newark, New Jersey
07/2004 –Present

Attending physician
Radiation Safety Officer
East Orange General Hospital, Newark, New Jersey
01/2017-Present

Attending physician
Department of Surgery
Tongji Medical University, Wuhan, China
07/1990 – 01/1993

OTHER PROFESSIONAL POSITIONS AND MAJOR VISITING APPOINTMENTS:

None

LICENSURE:

New York	230722	Inactivated
New Jersey	25MA07759500	Exp. 06/30/21

DRUG LICENSURE:

CDS	D08566100	Exp. 10/31/21
DEA	BL8976485	Exp. 03/31/22

CERTIFICATION:

American Board of Nuclear Medicine	Exp. 2023
Certification Board of Nuclear Cardiology	Exp. 2025

MEMBERSHIPS, OFFICES AND COMMITTEE ASSIGNMENTS IN PROFESSIONAL SOCIETIES:

The Society of Nuclear Medicine (SNM)
Member
2001 -Present

The Radiological Society of North America (RSNA)
Member
2004 –Present

HONORS AND AWARDS:

Best Teacher of Residents Award
Department of Radiology, NJMS
2012-2013
2015-2016
Editor's Recognition Award, Clinical Nuclear Medicine, 2016
NJ TopDocs 2018, 2019, 2020
Department of Radiology, NJMS

Faculty of the Year 2018-2019

BOARDS OF DIRECTORS / TRUSTEES POSITIONS:

None

SERVICE ON MAJOR COMMITTEES:

- A. Member, Institutional Review Board, New Jersey Medical School
2009 –Present
- B. Member, NJMS Continuing Medical Education Committee
07/2018-Present
- C. Member, Quality Committee
Society of Nuclear Medicine Molecular Imaging
07/2018-Present
- D. Editorial Boards
Clinical Nuclear Medicine (IF 6.28)
Medicine (Academic Editor, IF 2.13)
Frontiers in Oncology (Section Associate Editor, IF 4.85)
Molecular and Clinical Oncology
Journal of Radiology and Oncology (Executive Editor)
Nuclear Medicine and Radiology Journal (Editor)
Clinical Radiology & Imaging Journal (Editor)
Journal of Radiology and Medical Imaging (Associate Editor)
World Journal of Radiology
Journal of Radiology and Imaging
International Journal of Radiology
Annals of Clinical Radiology
Advanced Molecular Imaging and Interventional radiology
SRL Nuclear Medicine & Radiation Therapy
American Journal of Cancer Therapy and Pharmacology
American Journal of Cancer Case Reports
Journal of Tumor
World Journal of Methodology
International Journal of Cancer Research & Diagnosis
Austin Journal of HIV/AIDS Research
Case Reports in Pulmonology (Academic Editor)
- E. Journal Reviewer
Journal of Nuclear Medicine
Clinical Nuclear Medicine
Nuclear Medicine and Biology
Quarterly Journal of Nuclear Medicine and Molecular Imaging
Cancer Letters
Clinical Endocrinology
Journal of Molecular Endocrinology
Laboratory Investigation
Journal of Obstetrics and Gynecology Research
Clinical Genitourinary Cancer
Cancer Imaging
Others
- F. Advisor and member of Dissertation Committee for Ph.D. students
Keerthana Deepti Karunakaran, New Jersey Institute of Technology, 2018-2019
Yuyang Luo, New Jersey Institute of Technology, 2018-2019
Azeezat Azeez, New Jersey Institute of Technology, 2018-2019

TEACHING RESPONSIBILITIES:

Department of Radiology, New Jersey Medical School
Resident teaching including lectures and daily case interpretation
07/2004 –Present

New Jersey Medical School
Medical student teaching
07/2004 –Present

Department of Cardiology, New Jersey Medical School
Fellow teaching including daily case reading and monthly lecture
07/2004-Present

CLINICAL RESPONSIBILITIES:

University Hospital, Newark, New Jersey
Department of Radiology
Nuclear Medicine
Responsibilities include: Nuclear medicine procedures and interpretation; PET-CT interpretation
07/2004 –Present
East Orange General Hospital
Nuclear Medicine
01/2017-Present

GRANT HISTORY:

Society of Nuclear Medicine
Imaging of fatty acid oxidation in prostate cancer
Pilot Research Grant, \$10,000
February 2005 – January 2007

PUBLICATIONS:

A. Journal Articles H-Index 17 (based on SCOPUS in June 2019)

1. **Liu Y**, Franklin RB, Costello LC. Prolactin Specifically regulates citrate oxidation and m-aconitase of rat prostate epithelial cells. *Metabolism* 45:442-446, 1996
2. **Liu Y**, Franklin RB, Costello LC. Prolactin and testosterone regulation of mitochondrial Zinc in prostate epithelial cell. *Prostate* 30:26-31, 1997
3. Costello LC, **Liu Y**, Franklin RB. Zinc is a strong inhibitor of m-aconitase in prostate epithelial cells. *Journal of Biological Chemistry* 272:28875-28880, 1997
4. Costello LC, **Liu Y**, Franklin RB. Evidence for a zinc uptake transporter in human prostate cancer cells which is regulated by prolactin and testosterone. *Journal of Biological Chemistry* 274:17499-17503, 1999

5. Costello LC, Liu Y, Franklin RB. Testosterone stimulates the biosynthesis of m-aconitase and citrate oxidation in prostate. *Molecular and Cellular Endocrinology* 112:45-49, 1995
6. Costello LC, Liu Y, Franklin RB. Testosterone regulates pyruvate dehydrogenase E1 in prostate epithelial cells. *Endocrine Journal* 2:147-151, 1994
7. Costello LC, Y Liu and R Franklin. Prolactin specifically increases PDH-E1 in rat lateral prostate epithelial cells. *Prostate* 26:159-164, 1995
8. Costello LC, Liu Y, Franklin RB. Testosterone and prolactin stimulation of mitochondrial aconitase in pig prostate epithelial cells. *Urology* 48:654-659, 1996
9. Liang JY, Liu Y, Franklin RB, Costello LC, Feng P. Inhibition of zinc on human prostate carcinoma cell growth. *Prostate* 40:200-205, 1999
10. Costello L, Liu Y, Franklin RB. Mitochondrial aconitase gene expression is regulated by testosterone and prolactin in prostate epithelial cells. *Prostate* 15:196-205, 2000
11. Costello LC, Liu Y, Franklin RB. Zinc causes a shift toward citrate at equilibrium of the m-aconitase reaction of prostate mitochondria. *Journal of Inorganic Biochemistry* 30:161-166, 2000
12. Costello LC, Liu Y, Franklin RB. The pyruvate dehydrogenase E1 alpha gene is testosterone and prolactin regulated in prostate epithelial cells. *Endocrine Research* 26:23-28, 2000
13. Liu Y, Park T, Chun KJ, Freeman LM. Uterine myoma identified on a Tc-99m MAG3 of a renal transplant. *Clinical Nuclear Medicine* 27: 801-802, 2002
14. Liu Y, Chun KJ, Freeman LM. "Shin through" on dual tracer parathyroid scintigraphy: a potential pitfall in interpretation. *Clinical Nuclear Medicine* 30: 145-149, 2005
15. Liu Y, Ghesani NV, Zuckier LS. Does timing of lasix administration affect ability to tolerate diuretic renography? *Journal of Nuclear Medicine* 46:1317-1320, 2005
16. Liu Y, Ghesani NV, Mirani N, Zuckier LS. PET-CT demonstration of extensive muscle metastasis from breast cancer. *Clinical Nuclear Medicine* 31: 266-268, 2006
17. Liu Y. Radiolabelled somatostatin analog therapy in prostate cancer: current status and future directions (review paper). *Cancer Letter* 239: 21-26, 2006
18. Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. *Prostate Cancer and Prostate Disease* 9: 230-234, 2006
19. Bowers K, Liu Y, Ghesani N and Kim S. A level III sentinel lymph node in breast cancer. *World Journal of Surgical Oncology* 4: 31-34, 2006
20. Maldjian PD, Ghesani N, Ahmed S and Liu Y. Adenomyomatosis of the gallbladder: another cause for a "hot" gallbladder on F18-FDG PET. *American Journal of Roentgenology* 189:W36-W38, 2007
21. Liu Y. Metastatic brain lesions may demonstrate photopenia on FDG-PET. *Clinical Nuclear Medicine* 33:255-257, 2008
22. Liu Y. FDG PET-CT demonstration of metastatic neuroendocrine tumor of prostate. *World Journal of Surgical Oncology* 6:64-67, 2008

23. **Liu Y.** Bone marrow granulomatous inflammation: FDG-PET finding mimicking hematopoietic malignancy. *Clinical Nuclear Medicine* 33:707-708, 2008
24. **Liu Y.** Clinical significance of thyroid uptake on F18-fluorodeoxyglucose positron emission tomography (review paper). *Annals of Nuclear Medicine* 23:17-23, 2009
25. **Liu Y.** Benign ovarian and endometrial uptake on FDG-PET: patterns and pitfalls (review paper). *Annals of Nuclear Medicine* 23:107-112, 2009
26. **Liu Y.** Nodal metastasis from occult thyroid cancer detected by FDG PET-CT in a patient with two known malignancies. *Clinical Nuclear Medicine* 34:371-373, 2009
27. Cohen EC, Baredes S, Zuckier LS, Mirani N, **Liu Y** and Ghesani N. F18-FDG PET evaluation of sinonasal papilloma. *American Journal of Roentgenology* 193:214-217, 2009
28. **Liu Y.** Clinical significance of diffusely increased splenic uptake on FDG PET-CT (review paper). *Nuclear Medicine Communications* 30:763-769, 2009
29. **Liu Y.** Setting a high SUV cutoff is misleading and meaningless in the differentiation of benign and malignant lesions of the head and neck (Letter to Editor). *Nuclear Medicine Communications* 30:895, 2009
30. **Liu Y.** Benign orthopedic surgery related FDG uptake on PET-CT: case examples and pitfalls. *Annals of Nuclear Medicine* 23:701-708, 2009
31. **Liu Y,** Zuckier LS, Ghesani NV. Dominant uptake of fatty acid over glucose by prostate cells: a potential new diagnostic and therapeutic approach. *Anticancer Research* 30: 369-374, 2010
32. **Liu Y,** Ghesani NV, Zuckier LS. Physiology and pathophysiology of incidental findings detected on FDG-PET scintigraphy. *Seminars of Nuclear Medicine* 40: 294-315, 2010
33. **Liu Y.** Metastatic female adnexal tumor of possible wolffian origin (FATWO) of the appendix demonstrated by FDG PET-CT: the first reported case. *Clinical Nuclear Medicine* 36:136-137, 2011
34. **Liu Y.** Super-super scan on a bone scintigraphy. *Clinical Nuclear Medicine* 36: 227-228, 2011
35. **Liu Y.** Primary umbilical neoplasm demonstrated on FDG PET-CT. *Clinical Nuclear Medicine* 36: e-67-68, 2011
36. **Liu Y.** Characterization of thymic lesions with F18 FDG PET-CT: an emphasis of epithelial tumor. *Nuclear Medicine Communications* 32: 554-562, 2011
37. **Liu Y.** Demonstrations of AIDS-associated malignancies and infections at FDG PET-CT. *Annals Nuclear Medicine* 25: 536-546, 2011
38. **Liu Y.** Concurrent FDG avid nasopharyngeal lesion and generalized lymphadenopathy on PET-CT imaging is indicative of lymphoma in patients with HIV infection. *AIDS Research and Treatment*, online doi: 10.1155/2012/764291, 2012
39. **Liu Y.** Invalidity of SUV measurements of lesions in close proximity to hot sources due to “shine-through” effect on FDG PET-CT interpretation. *Radiology Research and Practice*, online doi: 10.1155/2012/867218, 2012
40. **Liu Y.** FDG PET-CT and renal scan demonstrations of carcinoma in the urinary bladder and bladder diverticulum. *Clinical Nuclear Medicine* 38:580-581, 2013

41. **Liu Y.** FDG PET differentiation of tumor recurrence from post-stereotactic radiosurgical scar in a central neurocytoma. *Clinical Nuclear Medicine* 38:469-470, 2013
42. **Liu Y.** Focal FDG uptake in the absence of CT abnormality on PET-CT: what is it? *World J Radiol* 5: 386-397, 2013
43. **Liu Y.** The role of FDG PET-CT in prostate cancer (invited review). *Euro Med J (Oncol)* 1: 61-67, 2013
44. **Liu Y.** Internal mammary node in breast cancer: controversial significance and role of positron emission tomography/computed tomography with F18-fluoro-2-deoxy-D-glucose (Invited Editorial). *Internal J Cancer Res Diag* 1: 1-3, 2013
45. **Liu Y.** Migrating tumor thrombus trapped within the Greenfield filter of the inferior vena cava and depicted by FDG PET-CT. *Clin Nucl Med* 39: 214-216, 2014
46. **Liu Y.** The diagnostic role of fluorodeoxyglucose positron emission tomography in prostate cancer. *Oncology Letters* 7: 2013-2018, 2014
47. **Liu Y.** Chronic sialadenitis with marked lymphadenopathy mimicking lymphoma on FDG PET-CT. *Clin Nucl Med* 39: 738-739, 2014
48. **Liu Y.** Imaging in Gynecology: Multiple distant adenomyosis mimicking carcinomatosis. *Amer. J. Obstet Gynecol* 210:486 e1-e2, 2014
49. **Liu Y.** The role of FDG PET-CT in initial staging of breast cancer. *World J Clin Oncol* 5: 982-989, 2014
50. **Liu Y.** Postoperative reactive lymphadenitis: a potential cause of false-positive FDG PET/CT. *World J Radiol* 6: 890-894, 2014
51. **Liu Y.** Disseminated AIDS-associated Burkitt's lymphoma demonstrated on FDG PET/CT. *Austin Journal of HIV/AIDS Research* 1 (2): 2, 2014
52. **Liu Y.** The role of 18F-FDG PET/CT in the follow-up of well-differentiated thyroid cancer with negative thyroglobulin but positive and/or elevated antithyroglobulin antibody. *Nucl Med Commun.*37: 577-582, 2016
53. **Liu Y.** Scintigraphic Images of Massive Tumoral Calcinosi. *Clin Nucl Med.* 2016; 41: 504-505.
54. **Liu Y.** Chronic Nonbacterial Osteomyelitis with FDG Avid Rib destruction and extensive lymphadenopathy. *Clin Nucl Med.* 41: 730-731, 2016
55. **Liu Y.** The Place of FDG PET/CT in renal cell carcinoma: value and limitations. *Frontiers in Oncology* 2016 Sep 6; 6:201. doi: 10.3389/fonc.2016.00201, 2016.
56. **Liu Y.** Images that Teach: The role of FDG uptake intensity in pericardial effusion. *Journal of Nuclear Cardiology* 24:1440-1441, 2017.
57. **Liu Y.** Hot lung spot without corresponding CT abnormality on FDG PET/CT: artifcatual or real, iatrogenic or pathologic? *Curr Prob Diag Rad.* 46: 200-203, 2017.
58. **Liu Y.** Massive idiopathic oropharyngeal and laryngeal granulomatosis on FDG PET/CT. *Clin Nucl Med* 42:325-32, 2017.

59. Liu Y. The role of FDG PET/CT in staging and restaging primary bone lymphoma. *Nucl Med Communications* 38:319-324, 2017.
60. Liu Y. Blockage of sulfur colloid migration on lymphoscintigraphy and intravascular focus on FDG PET/CT secondary to an occluded hemodialysis fistula. Accepted by *Annals of Clinical Radiology*.
61. Liu Y. F18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Bone Hemangiopericytoma. *Molecular and Clinical Oncology* 7:1147-1151, 2017.
62. Liu Y. Lung Neoplasms with low F18-fluorodeoxyglucose avidity. *PET Clin* 13: 11-18, 2018.
63. Liu Y. Septic and tumor thrombosis caught by inferior vena cava filters and demonstrated on FDG PET-CT. *Vascular Medicine* 23: 491-492, 2018.
64. Liu Y. Imaging in Gynecology: Actinomycosis induced adnexal and uterine masses mimicking malignancy on FDG PET/CT. *Amer. J. Obstet Gynecol* 220: 281, 2019.
65. Liu Y. Focal mass-like cardiac uptake on oncologic FDG PET/CT: real lesion or atypical pattern of physiologic uptake? *J Nucl Cardiol* 26: 1205-1211, 2019.
66. Liu Y. FDG PET/CT for metastatic squamous cell carcinoma of unknown primary of the head and neck. *Oral Oncology* 92: 46-51, 2019.
67. Liu Y. Giant primary breast Burkitt's lymphoma demonstrated on FDG PET/CT. *Breast J.* 26:1039-1040, 2020.
68. Liu Y. Pseudomyogenic hemangioendothelioma: distinctive FDG PET/CT findings with numerous multilayer lesions in a single distal extremity. *Clin Nucl Med* 45:248-249, 2020.
69. Liu Y. Large idiopathic mesenteric necrotizing granuloma mimicking metastatic disease on FDG PET/CT. *Clin Nucl Med* 45:314-315, 2020.
70. Ma S, Liu Y. The diagnostic value of F18 FDG PET/CT in sublingual and submandibular gland tumors. 2020 Oct;13 (4):27. doi: 10.3892/mco.2020.2097. Epub 2020 Jul 20
71. Zheng J, Liu Y. Tc-99m Leukocyte Scintigraphy Revealed Viral Pulmonary Infection in a Covid-19 Patient. *Clin Nucl Med*, 2020 Jul 17. doi: 10.1097/RLU.0000000000003219. Online ahead of print.
- B. Books and Chapters**
- Liu Y, Blaifox MD. Use of radionuclides to study renal function. In: Michael S. Golligorsky (ed). *Renal Disease: Guide to technical approaches*. Pages 79-117; The Humana Press Inc.: New Jersey, 2003
- Liu Y. New therapeutic strategies in prostate cancer. In Holcroft R (ed). *Treatment Strategies in Oncology*. The Cambridge Research Center, London, 2010
- Liu Y. Radionuclide imaging in prostate cancer. In Schwab M (ed): *The Encyclopedia of Cancer*, Heidelberg, Springer Science Publisher, 3rd Edition 2011; 4th Edition 2016. DOI 10.1007/978-3-642-27841-9_6795-3

PRESENTATIONS

1. Zuckier LS, Freeman LM, Ghesani NV and Liu Y. Organs they never taught you about in bone scan school: Localization and significance of nonosseous neurologic uptake observed during bone scintigraphy. RSNNA, Chicago, 2009. (Educational Exhibit)
2. Ghesani N, Baladandapani P, Clarke KO, Hameed M, Liu Y and Zuckier LS. Correlation of hormone receptor (HR) and HER2/NEU receptor (H2NR) status with peak 18F FDG (FDG) tumor uptake, a non-invasive method of disease characterization in breast cancer. 2008 World Molecular Imaging Congress (WMIC 2008), Nice, France, September 10-13, 2008
3. Billihymer ME, Beebe K, Benevenia J, Patterson F, Sheen L, Liu Y, Hameed M, Tuy B, Zuckier L and Ghesani N. Utility of PET/CT in evaluation of patients presenting with primary bone lymphoma. Society of Nuclear Medicine 55th Annual Meeting, New Orleans, June 2008
4. Liu Y, Zuckier L and Ghesani N. Fatty acid rather than glucose metabolism is the dominant bioenergetic pathway in prostate cancer. Society of Nuclear Medicine 55th Annual Meeting, New Orleans, June 2008
5. Zuckier LS, Ghesani NV and Liu Y. Reduced perspicuity of focal FDG-PET abnormalities when fused with CT images. Medical Image Perception Conference XII. October 17 - 20, 2007, The University of Iowa Iowa City, IA.
6. Zuckier LS, Kolano J, Liu Y and Ghesani NV. Results and outcome of 191 brain-death studies using diffusible blood flow radiopharmaceuticals: analysis of 26 patients with cerebral perfusion. Poster presentation, 54th Annual Society of Nuclear Medicine Meeting, Washington DC, June 4, 2007.
7. Zuckier LS. Ghesani NV, Liu Y. Perspicuity of solitary oncologic lesions on fused ¹⁸F-FDG PET-CT images. Poster presentation, 54th Annual Society of Nuclear Medicine Meeting, Washington DC, June 5, 2007
8. Mahmood Y, Zuckier LS, Cohen EG, Mirani N, Hameed M, Liu Y, Beredes S and Ghesani NV. ¹⁸F-Fluorodeoxyglucose (FDG) PET/CT-based evaluation of estheseioneurolastoma: Correlating standardized uptake value with histological tumor grade. 54th Annual Society of Nuclear Medicine Meeting, Washington DC, June 5, 2007. Poster presentation.
9. Mahmood Y, Cohen EG, Baredes S, Zuckier LZ, Liu Y, Mirani NM, Hameed M, Ghesani NV. ¹⁸F-Fluorodeoxyglucose (FDG) PET/CT-Based Staging of Estheseioneurolastoma? 6th Asian Oceanian Congress of Neuroradiology and Head & Neck Radiology (AOCNHNR), February, 2007, Singapore. Poster presentation.
10. Kertzman J, Cohen EG, Baredes S, Zuckier LS, Liu Y, Ghesani NV. Co-registered Positron Emission Tomography and Computed Tomography (PET/CT) Evaluation of Sinonasal Inverted Papilloma. Triological Society Combined Sections Meeting, Marco Island, FL, Feb 14-18, 2007.

11. Ghesani NV, Cohen EG, Baredes S, **Liu Y**, and Zuckier LS. Utility of whole-body FDG-PET/CT scan in patients (pts) with resectable oral cavity and oropharyngeal carcinoma in predicting cervical lymph node (LN) metastasis at surgery. Oral presentation, 11/28/2006, RSNA 2006.
12. Sharma S, Ertel NH, Zuckier LS, **Liu Y**. Flip-Flop phenomenon in follicular thyroid carcinoma suggesting genetic evolution of the tumor. Poster presentation. Endocrine Society's 88th Annual Meeting, Boston, MA, June 24, 2006
13. Ghesani NV, Harrison LE, Cohen EG, Baredes S, **Liu Y**, Rice P Zuckier LS. Significance of increased, focal, FDG uptake of the gastrointestinal tract observed on whole body PET-CT scans performed in patients with head and neck primary neoplasms. Oral presentation, 53rd Annual Society of Nuclear Medicine Meeting, San Diego, CA, June 5, 2006. Appears in Journal of Nuclear Medicine 47: p, 2006.
14. Zuckier LS, **Liu Y**, Kim EL, Ghesani N and Rauscher S. Does F-15 or F+0 lasix renography require 30 minutes of imaging post-MAG3? Poster presentation, 53rd Annual Society of Nuclear Medicine Meeting, San Diego, CA, June 5, 2006. Appears in Journal of Nuclear Medicine 47: 359p, 2006.
15. Ghesani N, Pliner LF, **Liu Y**, Zuckier L, Chokhavatia S. Metastatic sigmoid adenocarcinoma presenting as pseudomyxoma peritonei. Poster presentation. American College of Gastroenterology 70th Annual Scientific Meeting, Honolulu, Oct. 29 – November 2, 2005. Appears in American J of Gastroenterology 2005;100:S264
16. **Liu Y**, Zuckier LS and Ghesani NV. Does timing of lasix administration affect patient ability to tolerate diuretic renography? Oral presentation, 52nd Annual Society of Nuclear Medicine Meeting, Toronto, Canada, June 19, 2005. Appears in Journal of Nuclear Medicine 46:23p, 2005.
17. **Liu Y**, Zuckier LS and Ghesani NV. Does timing of lasix administration affect patient ability to tolerate diuretic renography? 18th Annual Northeast Regional Scientific Meeting of the Society of Nuclear Medicine, October 22 - 24, 2004, Stamford Connecticut. Appears in Clinical Nuclear Medicine 30:374, 2005.
18. **Liu Y**. The role of FDG PET/CT in staging and restaging primary bone lymphoma. Oral presentation, 64nd Annual Society of Nuclear Medicine Meeting, Denver, Colorado, June10-14, 2017.
19. **Liu Y**. FDG PET/CT for metastatic squamous cell carcinoma of unknown primary of the head and neck. E-poster, 31 European Association of Nuclear Medicine, Dusseldorf, Germany, October 13-17, 2018
20. **Ma S, Y Liu**. The diagnostic value of F18 FDG PET/CT in sublingual and submandibular gland tumors. Oral presentation at American Society of Head and Neck Radiology's 53rd Annual Conference, Scottsdale, Arizona, October 2-6, 2019